These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31789677)

  • 1. Fatty liver, cardiometabolic disease and mortality.
    Bedogni G; Gastaldelli A; Foschi FG
    Curr Opin Lipidol; 2020 Feb; 31(1):27-31. PubMed ID: 31789677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extrahepatic complications of nonalcoholic fatty liver disease.
    Armstrong MJ; Adams LA; Canbay A; Syn WK
    Hepatology; 2014 Mar; 59(3):1174-97. PubMed ID: 24002776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population.
    Stepanova M; Younossi ZM
    Clin Gastroenterol Hepatol; 2012 Jun; 10(6):646-50. PubMed ID: 22245962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease (NAFLD): a new risk factor for adverse cardiovascular events in dialysis patients.
    Mikolasevic I; Racki S; Zaputovic L; Lukenda V; Milic S; Orlic L
    Med Hypotheses; 2014 Feb; 82(2):205-8. PubMed ID: 24365277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease and vascular risk.
    Bhatia LS; Curzen NP; Byrne CD
    Curr Opin Cardiol; 2012 Jul; 27(4):420-8. PubMed ID: 22596186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of patients with NAFLD and elevated liver enzymes.
    Ekstedt M; Franzén LE; Mathiesen UL; Thorelius L; Holmqvist M; Bodemar G; Kechagias S
    Hepatology; 2006 Oct; 44(4):865-73. PubMed ID: 17006923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interactions of nonalcoholic fatty liver disease and cardiovascular diseases.
    Perazzo H; Poynard T; Dufour JF
    Clin Liver Dis; 2014 Feb; 18(1):233-48. PubMed ID: 24274877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease and cardiovascular risk.
    Misra VL; Khashab M; Chalasani N
    Curr Gastroenterol Rep; 2009 Feb; 11(1):50-5. PubMed ID: 19166659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications.
    Targher G; Byrne CD
    J Clin Endocrinol Metab; 2013 Feb; 98(2):483-95. PubMed ID: 23293330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
    Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
    PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.
    Santos RD; Valenti L; Romeo S
    Atherosclerosis; 2019 Mar; 282():110-120. PubMed ID: 30731283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease and cardiovascular disease.
    Hyogo H; Chayama K; Yamagishi S
    Curr Pharm Des; 2014; 20(14):2403-11. PubMed ID: 23844815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
    Budd J; Cusi K
    Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of patients with nonalcoholic fatty liver.
    Rafiq N; Bai C; Fang Y; Srishord M; McCullough A; Gramlich T; Younossi ZM
    Clin Gastroenterol Hepatol; 2009 Feb; 7(2):234-8. PubMed ID: 19049831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fatty liver and global cardiometabolic risk].
    Szollár L
    Orv Hetil; 2010 Nov; 151(47):1946-50. PubMed ID: 21071306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspective: nonalcoholic fatty liver disease and cardiovascular risk.
    Nestel PJ; Mensink RP
    Curr Opin Lipidol; 2013 Feb; 24(1):1-3. PubMed ID: 23298957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 20. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data.
    Ghouri N; Preiss D; Sattar N
    Hepatology; 2010 Sep; 52(3):1156-61. PubMed ID: 20658466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.